IGF2BP1 and neoplasm: For example, research has highlighted that the small molecule cucurbitacin B (CuB) can effectively target IGF2BP1, inhibit the recognition of c-MYC by IGF2BP1, induce apoptosis, potentially recruit immune cells to the tumor microenvironment, and suppress the expression of PD-L1, thereby demonstrating anti-HCC effects [120].